Mina Nikanjam

3.2k total citations · 2 hit papers
68 papers, 1.9k citations indexed

About

Mina Nikanjam is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mina Nikanjam has authored 68 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 23 papers in Cancer Research and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mina Nikanjam's work include Cancer Genomics and Diagnostics (20 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Mina Nikanjam is often cited by papers focused on Cancer Genomics and Diagnostics (20 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Mina Nikanjam collaborates with scholars based in United States, Netherlands and United Kingdom. Mina Nikanjam's co-authors include Razelle Kurzrock, Shumei Kato, Apostolia M. Tsimberidou, Elena Fountzilas, Thomas F. Budinger, Trudy M. Forte, Edmund V. Capparelli, C. Anthony Hunt, Andrew R. Gibbs and Xiao Ou Shu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Reviews Drug Discovery.

In The Last Decade

Mina Nikanjam

63 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liquid biopsy: current technology and clinical applications

2022 501 citations Mina Nikanjam, Shumei Kato et al. Journal of Hematology & Oncology profile →
Review of precision cancer medicine: Evolution of the treatment paradigm

2020 418 citations Mina Nikanjam, Razelle Kurzrock et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mina Nikanjam United States	19	696	672	658	348	189	68	1.9k
Salvatore Pisconti Italy	22	396 0.6×	692 1.0×	502 0.8×	434 1.2×	154 0.8×	97	1.7k
Yong S. Chang United States	21	461 0.7×	530 0.8×	1.0k 1.6×	290 0.8×	120 0.6×	36	2.2k
Kristina W. Thiel United States	28	469 0.7×	539 0.8×	1.7k 2.5×	177 0.5×	249 1.3×	63	2.7k
Qi Zhou China	26	518 0.7×	872 1.3×	938 1.4×	286 0.8×	438 2.3×	99	2.2k
Alexander J. Chou United States	25	503 0.7×	726 1.1×	931 1.4×	1.1k 3.2×	223 1.2×	61	2.4k
Deepa S. Subramaniam United States	25	378 0.5×	922 1.4×	810 1.2×	793 2.3×	205 1.1×	81	2.2k
Xing Zhang China	27	652 0.9×	917 1.4×	1.2k 1.8×	423 1.2×	327 1.7×	126	2.4k
Pia Vihinen Finland	21	832 1.2×	959 1.4×	802 1.2×	142 0.4×	210 1.1×	55	2.0k
Hannelore Denys Belgium	28	734 1.1×	1.3k 1.9×	1.1k 1.7×	358 1.0×	313 1.7×	148	3.1k
Véronique Cocquyt Belgium	24	925 1.3×	950 1.4×	1.4k 2.1×	210 0.6×	224 1.2×	47	2.9k

Countries citing papers authored by Mina Nikanjam

Since Specialization

Citations

This map shows the geographic impact of Mina Nikanjam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mina Nikanjam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mina Nikanjam more than expected).

Fields of papers citing papers by Mina Nikanjam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mina Nikanjam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mina Nikanjam. The network helps show where Mina Nikanjam may publish in the future.

Co-authorship network of co-authors of Mina Nikanjam

This figure shows the co-authorship network connecting the top 25 collaborators of Mina Nikanjam. A scholar is included among the top collaborators of Mina Nikanjam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mina Nikanjam. Mina Nikanjam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sicklick, Jason K., Daisuke Nishizaki, Hirotaka Miyashita, et al.. (2026). Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations. Journal of Clinical Oncology. 44(7). 540–552.

Adashek, Jacob J., Mina Nikanjam, & Razelle Kurzrock. (2025). Tumour-agnostic kinase inhibitors. Nature Reviews Drug Discovery. 24(7). 504–520. 4 indexed citations

Nikanjam, Mina, et al.. (2025). Nectin-4 expression patterns and therapeutics in oncology. Cancer Letters. 622. 217681–217681. 5 indexed citations

Nikanjam, Mina, et al.. (2025). Novel clinical trial designs emerging from the molecular reclassification of cancer. CA A Cancer Journal for Clinicians. 75(3). 243–267. 3 indexed citations

Nikanjam, Mina & Razelle Kurzrock. (2025). Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies. Seminars in Cancer Biology. 117. 57–68.

Kato, Shumei, Mina Nikanjam, Aditya Shreenivas, et al.. (2024). On the right TRACK: Providing comprehensive genomic profiling (CGP) and molecular tumor board (MTB) for patients (pts) with rare cancers.. Journal of Clinical Oncology. 42(16_suppl). 3127–3127. 2 indexed citations

Nishizaki, Daisuke, Razelle Kurzrock, Hirotaka Miyashita, et al.. (2024). Viewing the immune checkpoint VISTA: landscape and outcomes across cancers. ESMO Open. 9(4). 102942–102942. 18 indexed citations

Nikanjam, Mina, Shumei Kato, Jason K. Sicklick, & Razelle Kurzrock. (2023). At the right dose: personalised (N-of-1) dosing for precision oncology. European Journal of Cancer. 194. 113359–113359. 8 indexed citations

Choi, Sharon, Razelle Kurzrock, Thomas J. O’Keefe, et al.. (2023). BTLA transcriptomic expression correlates with high levels of PD-1, PD-L2, and CTLA-4 checkpoints and with its ligand, HVEM, across diverse solid cancers.. Journal of Clinical Oncology. 41(16_suppl). e14641–e14641.

10.

Nikanjam, Mina, Shumei Kato, & Razelle Kurzrock. (2022). Liquid biopsy: current technology and clinical applications. Journal of Hematology & Oncology. 15(1). 131–131. 501 indexed citations breakdown →

11.

Nikanjam, Mina, et al.. (2022). Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series. Journal of Medical Case Reports. 16(1). 337–337. 2 indexed citations

12.

Nikanjam, Mina, et al.. (2021). BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. Molecular Cancer Therapeutics. 20(6). 1072–1079. 8 indexed citations

13.

Jahromi, Amin Haghighat, Donald A. Barkauskas, Matthew Zabel, et al.. (2020). Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Research. 10(1). 150–150. 10 indexed citations

14.

Poddar, Soumya, Edmund V. Capparelli, Ethan W. Rosser, et al.. (2019). Development and preclinical pharmacology of a novel dCK inhibitor, DI-87. Biochemical Pharmacology. 172. 113742–113742. 9 indexed citations

15.

Nikanjam, Mina, Jin Yang, & Edmund V. Capparelli. (2019). Population pharmacokinetics of siltuximab: impact of disease state. Cancer Chemotherapy and Pharmacology. 84(5). 993–1001. 9 indexed citations

16.

Nikanjam, Mina, et al.. (2019). Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemotherapy and Pharmacology. 84(6). 1339–1348. 39 indexed citations

17.

Nikanjam, Mina, et al.. (2018). Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Annals of Oncology. 29(11). 2192–2199. 40 indexed citations

18.

Nikanjam, Mina, Eleanor A. Blakely, Kathleen A. Bjornstad, et al.. (2006). Synthetic Nano-Low Density Lipoprotein as Targeted Drug Delivery Vehicle for Glioblastoma \nMultiforme. eScholarship (California Digital Library). 96 indexed citations

19.

Nikanjam, Mina, Eleanor A. Blakely, Kathleen A. Bjornstad, et al.. (2006). Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. International Journal of Pharmaceutics. 328(1). 86–94. 5 indexed citations

20.

Nikanjam, Mina, et al.. (2006). Finger flexor motor control patterns during active flexion: An in vivo tendon force study. Human Movement Science. 26(1). 1–10. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact